Stroke recurrence is a serious concern — roughly 1 in 4 strokes occur in people who’ve already had one.
Preventing recurrent stroke requires a comprehensive, etiology-based approach that includes antithrombotic therapy, aggressive risk factor modification, and in select cases, procedural interventions.
Prevention strategies should be tailored to the specific stroke subtype, with management of vascular risk factors—particularly hypertension—being critically important across all etiologies.
The choice of antithrombotic therapy depends primarily on stroke etiology and severity.
For noncardioembolic minor strokes (NIH Stroke Scale ≤3) or high-risk TIA (ABCD2 score ≥4), dual antiplatelet therapy (DAPT) with aspirin and clopidogrel initiated within 72 hours and continued for 21-30 days significantly reduces early recurrent stroke risk, followed by long-term single antiplatelet therapy.
The CHANCE trial demonstrated that dual anti platelet approach reduces 90-day stroke recurrence from 11.7% to 8.2% compared to aspirin alone.
Ticagrelor plus aspirin is an alternative DAPT regimen, now FDA-approved for acute ischemic stroke or high-risk TIA.
For cardioembolic strokes, particularly those associated with atrial fibrillation, direct oral anticoagulants (DOACs) are preferred over warfarin due to a 50% reduction in hemorrhagic stroke risk.
Long-term antiplatelet monotherapy with aspirin or clopidogrel is recommended for most other stroke subtypes.
Medications
Antiplatelets & Anticoagulants
Blood pressure lowering reduces recurrent stroke risk by 20-40%, with greater reductions in systolic (>11 mm Hg) and diastolic (>4 mm Hg) blood pressure providing the most benefit.
High blood pressure is the #1 modifiable risk factor for stroke
Target is typically below 130/80 mmHg
ACE inhibitors, angiotensin receptor blockers (ARBs), and thiazide diuretics are commonly used
Lipid Management
Target LDL cholesterol with high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20 mg daily) reduces recurrent stroke risk by approximately 19%.
For patients with atherosclerotic stroke,If LDL goals cannot be achieved with statins alone, adding ezetimibe or PCSK9 inhibitors is recommended.
Target HbA1c: 12345614GLP-1 receptor agonists and SGLT2 inhibitors should be considered as they reduce cardiovascular events and stroke risk by approximately 15% in patients with diabetes.
Lifestyle Modifications
The Mediterranean or DASH diet), physical activity (moderate-intensity aerobic activity at least 4 times weekly, tobacco cessation, weight optimization, and adequate sleep.
For patients with severe carotid stenosis (70-99%) ipsilateral to a nondisabling stroke or TIA, carotid revascularization (endarterectomy or stenting) should be performed relatively early, with a number needed to treat of 9 to prevent one ipsilateral stroke.
In contrast, intracranial stenosis should be managed with aggressive medical therapy and short-term DAPT rather than angioplasty/stenting.
Patent foramen ovale (PFO) closure is reasonable for patients aged 18-60 years with nonlacunar cryptogenic stroke and high-risk PFO features.
Prolonged cardiac monitoring is recommended to detect occult atrial fibrillation in patients with cryptogenic stroke.
After a stroke of unclear cause (cryptogenic stroke), extended cardiac monitoring (30-day or implantable loop recorder) is often recommended to detect paroxysmal atrial fibrillation, which may be intermittent and easily missed.
Screening and treatment for obstructive sleep apnea may provide additional benefit, particularly in moderate to severe cases.
Importantly, empiric anticoagulation is not recommended for embolic stroke of undetermined source (ESUS), as trials showed no benefit over antiplatelet therapy.
Among patients with non-cardioembolic ischemic stroke or high risk TIA treated with anti-platelet therapy, asundexian at a daily dose of 50 mg resulted in the lower risk of a ischemic stroke and major cardiovascular events, and then placebo, without a higher risk of major bleeding (OCEANIC-STROKE investigators).
Managing Underlying Conditions
Atrial fibrillation — anticoagulation and rate/rhythm control are essential; AFib raises stroke risk 5× and accounts for ~20% of strokes
Carotid artery stenosis — significant narrowing (>70%) may require carotid endarterectomy or stenting
Diabetes — tight glycemic control reduces vascular damage
Sleep apnea — CPAP treatment lowers blood pressure and reduces cardiovascular risk